

## Sontuzumab

Cat. No.:	HY-P99591
CAS No.:	372075-37-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Sontuzumab (AS1402) is a humanized IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a $K_d$ of ~1 nM. Sontuzumab can be used for the research of breast cancer <sup>[1]</sup> .
IC <sub>50</sub> & Target	Kd: ~1 nM (MUC1) <sup>[1]</sup>
In Vitro	Sontuzumab (huHMFG-1; 0-25 µg/mL) induces antibody-dependent cellular cytotoxicity (ADCC) in the breast tumor cell line ZR-75-1, in three bone marrow-derived tumor cell lines from breast cancer patients (KM22, 1590, HG15), and in Chinese hamster ovary (CHO) cells transfected with the human MUC1 gene, by using peripheral blood mononuclear cells (PBMCs) from healthy donors. Cell lines that do not express human MUC1 are not susceptible to ADCC in the presence of Sontuzumab <sup>[1][2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Pegram MD, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. *Breast Cancer Res.* 2009;11(5):R73.

[2]. Snijdewint FG, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. *Int J Cancer.* 2001 Jul 1;93(1):97-106.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA